WOUND HEALING COMPOSITIONS AND TREATMENTS

摘要

This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

主权项

1. A method of treating a refractory wound, comprising:
measuring the size a skin wound upon initial presentation for treatment to obtain a first size measurement; administering standard of care such as compression bandaging and/or off-loading to the wound; measuring the size of the wound after 2-4 weeks of administering the standard of care to obtain a second size measurement; determining that the second size indicator of the wound is within a predetermined range from about −30 to about +35% of the first size measurement, thereby identifying a refractory wound; and administering to the refractory wound a pharmaceutical composition comprising a pharmaceutical carrier suitable for topical administration of an anti-connexin polynucleotide to a connexin selected from connexin 26, connexin 30 and connexin 43.